Guangdong Lewwin Pharmaceutical Research Institute

Guangdong Lewwin Pharmaceutical Research Institute is a premier research-oriented contract research organization (CRO) based in Guangzhou, China, specializing in non-clinical drug evaluation. It holds the distinction of being the first institution in South China to receive full GLP certification from the NMPA and the first in China to pass an unannounced FDA GLP inspection. The institute offers a comprehensive range of services, including safety evaluation, pharmacodynamics, pharmacokinetics, and bioanalysis, supporting the development of small molecules, traditional Chinese medicines, and advanced biologics. Beyond its CRO services, Lewwin is actively involved in the research and development of innovative therapies, with a pipeline featuring programs in influenza, ophthalmology, and acute kidney injury. Recognized as a national 'Little Giant' enterprise, the company operates multiple state-level research platforms and maintains international standards through AAALAC accreditation.